CIRCULATING IRISIN LEVEL IN DIAGNOSED PATIENTS WITH METABOLIC SYNDROME

ABSTRACT Background: Metabolic syndrome is characterized by reversible diagnostic components such as reduced serum HDL-cholesterol, raised serum triglycerides, increase serum glucose concentration, increase blood pressure, all of which are related to large waist circumference. Irisin is an adipokine hormone that is mostly secreted by white subcutaneous adipose tissue and has a critical regulatory function in lipid metabolism. The present study aimed to evaluate serum irisin level among metabolic syndrome. Materials and methods: A case control study was conducted among138 individuals, 69 patients with metabolic syndrome and 69 healthy individuals as a control group. The study was conducted from June 2022 to June 2023After a night of fasting, blood samples were taken the next morning. Glucose, insulin, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and blood HbA1c% were all determined using the Cobas 6000 (Hitachi, Roche) device, with the exception of serum irisin, which was determined using an ELISA. Results: The MS participants have higher percentage of high irisin levels compared to control participants with statistically significant differences (37 (53.6%); 24 (34.8%); p=0.039). Furthermore; there were insignificant differences between the mean ±SD levels of serum irisin of the studied groups (p=0.220). Conclusion: Mean serum irisin level was higher among MS patients compared to healthy individuals, as well as, serum irisin levels had a positive correlation with isolated component of MS such as waist circumference, dyslipidemia and impaired glucos e metabolism.